188 related articles for article (PubMed ID: 35482320)
21. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.
Ross JS; Mulvey GK; Hines EM; Nissen SE; Krumholz HM
PLoS Med; 2009 Sep; 6(9):e1000144. PubMed ID: 19901971
[TBL] [Abstract][Full Text] [Related]
22. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA.
Talebi R; Redberg RF; Ross JS
Trials; 2020 Jul; 21(1):675. PubMed ID: 32703252
[TBL] [Abstract][Full Text] [Related]
23. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review.
Beytout Q; Afach S; Guelimi R; Sbidian E; Le Cleach L
J Clin Epidemiol; 2024 May; ():111406. PubMed ID: 38825170
[TBL] [Abstract][Full Text] [Related]
24. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
25. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
[TBL] [Abstract][Full Text] [Related]
26. Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials.
Perlmutter AS; Tran VT; Dechartres A; Ravaud P
Ann Oncol; 2017 Apr; 28(4):688-695. PubMed ID: 28011448
[TBL] [Abstract][Full Text] [Related]
27. Non-steroidal anti-inflammatory drugs for acute gout.
van Durme CM; Wechalekar MD; Buchbinder R; Schlesinger N; van der Heijde D; Landewé RB
Cochrane Database Syst Rev; 2014 Sep; (9):CD010120. PubMed ID: 25225849
[TBL] [Abstract][Full Text] [Related]
28. Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.
Withycombe B; Ovenell M; Meeker A; Ahmed SM; Hartung DM
J Clin Epidemiol; 2016 Sep; 77():78-83. PubMed ID: 27108488
[TBL] [Abstract][Full Text] [Related]
29. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study.
Prayle AP; Hurley MN; Smyth AR
BMJ; 2012 Jan; 344():d7373. PubMed ID: 22214756
[TBL] [Abstract][Full Text] [Related]
30. Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov-evaluation of a new tracking tool for the US clinical trial registry.
Keestra SM; Rodgers F; Lenz D; Osborne R; Bruckner T; Lee S
Trials; 2021 Jun; 22(1):375. PubMed ID: 34074329
[TBL] [Abstract][Full Text] [Related]
31. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
32. Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov.
Baudart M; Ravaud P; Baron G; Dechartres A; Haneef R; Boutron I
BMC Med; 2016 Jan; 14():7. PubMed ID: 26819213
[TBL] [Abstract][Full Text] [Related]
33. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study.
Hughes S; Cohen D; Jaggi R
BMJ Open; 2014 Jul; 4(7):e005535. PubMed ID: 25009136
[TBL] [Abstract][Full Text] [Related]
34. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
35. Do Published Data in Trials Assessing Cancer Drugs Reflect the Real Picture of Efficacy and Safety?
Lv JW; Chen YP; Zhou GQ; Liu X; Guo Y; Mao YP; Ma J; Sun Y
J Natl Compr Canc Netw; 2017 Nov; 15(11):1363-1371. PubMed ID: 29118228
[No Abstract] [Full Text] [Related]
36. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review.
Paludan-Müller AS; Créquit P; Boutron I
BMC Med; 2021 Apr; 19(1):88. PubMed ID: 33827569
[TBL] [Abstract][Full Text] [Related]
37. Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.
Wang L; Rouse B; Marks-Anglin A; Duan R; Shi Q; Quach K; Chen Y; Cameron C; Schmid CH; Li T
J Clin Epidemiol; 2019 Oct; 114():84-94. PubMed ID: 31226413
[TBL] [Abstract][Full Text] [Related]
38. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
